November 07, 2008: Santhera Presents Preclinical Data on Oral MC4 Receptor Antagonists for Treatment of Cancer Cachexia at AICR Research Conference

07.11.08 - 09:25 ... source : Santhera Pharmaceuticals

... News release MC4Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, today announced preclinical data on a novel generation of melanocortin-4 (MC4) receptor antagonists for potential treatment of cancer cachexia (severe muscle wasting). The most advanced candidates significantly increase food intake in healthy animals and prevent cancer-induced body weight loss in disease-relevant models. In-vivo data will be presented today at the 2008 Research Conference on Food, Nutrition, Physical Activity & Cancer of the American Institute for Cancer Research (AICR) in Washington DC [1]. Santhera's two novel, yet chemically unrelated MC4 receptor antagonists were both found to significantly increase appetite in healthy mice. In studies of mice carrying a C26 adenocarcinoma repea ...» Next (HTML)